GOVX GeoVax Labs, Inc.
USHealthcareAs of 2026-07-10 16:00
Why GOVX matters now
GeoVax Labs, Inc. (GOVX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.18 with +0.85% on the session and $1.1M in market capitalization; recent performance reads 1-month -33.33% and YTD -68.69%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.3M, and EPS of $-2.62. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1483.8%.
The latest indexable market news headline is "GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $100.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.45
P/S
1.51
EV/EBITDA
-0.02
DCF Value
$0.72
FCF Yield
-1483.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
104.0%
Operating Margin
-2523.4%
Net Margin
-2507.3%
ROE
-709.5%
ROA
-716.5%
ROIC
-2421.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.3M | $-2.62 |
| Q4 2025 | $0.00 | $-4.4M | $-2.55 |
| FY 2025 | $2.5M | $-21.5M | $-22.40 |
| Q3 2025 | $0.00 | $-6.3M | $-7.75 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$100.00
Target (Median)
$100.00
Target Range
$100.00 - $100.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.62
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.